The level of patient monitoring needed to support a COVID-19 trial has typically only been achieved in hospitals. Enter decentralized clinical trials. DCTs can take symptomatic patients with COVID19, who are recovering at home, and involve them in a safe and effective remote study. In this presentation, we are joined by client RedHill Biopharma to detail insights from our pioneering interventional COVID-19 DCT utilizing integrated digital devices, next-gen ePRO, telehealth, and in-home visits by HCPs.
Interested in Viewing the Webinar?
Fill out the form below for access.
ObvioHealth studies are run on our purpose-built platform by our own in-house virtual team. This allows us to work seamlessly from protocol design all the way through to analysis and reporting.
Up to 4x
3 mo ObvioHealth average vs 12 mo benchmark for site-based trials
average retention vs. 70% benchmark for traditional trials
average per study (digital questionnaires, daily ediary, etc.).